Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance.

Pflug N, Cramer P, Robrecht S, Bahlo J, Westermann A, Fink AM, Schrader A, Mayer P, Oberbeck S, Seiler T, Zenz T, Dürig J, Kreuzer KA, Stilgenbauer S, Eichhorst B, Hallek M, Herling M, Hopfinger G.

Leuk Lymphoma. 2018 Sep 20:1-9. doi: 10.1080/10428194.2018.1488253. [Epub ahead of print]

PMID:
30234404
2.

Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.

Schrader A, Crispatzu G, Oberbeck S, Mayer P, Pützer S, von Jan J, Vasyutina E, Warner K, Weit N, Pflug N, Braun T, Andersson EI, Yadav B, Riabinska A, Maurer B, Ventura Ferreira MS, Beier F, Altmüller J, Lanasa M, Herling CD, Haferlach T, Stilgenbauer S, Hopfinger G, Peifer M, Brümmendorf TH, Nürnberg P, Elenitoba-Johnson KSJ, Zha S, Hallek M, Moriggl R, Reinhardt HC, Stern MH, Mustjoki S, Newrzela S, Frommolt P, Herling M.

Nat Commun. 2018 Feb 15;9(1):697. doi: 10.1038/s41467-017-02688-6.

3.

Environmental photochemistry of dienogest: phototransformation to estrogenic products and increased environmental persistence via reversible photohydration.

Pflug NC, Hankard MK, Berg SM, O'Connor M, Gloer JB, Kolodziej EP, Cwiertny DM, Wammer KH.

Environ Sci Process Impacts. 2017 Nov 15;19(11):1414-1426. doi: 10.1039/c7em00346c.

PMID:
29034382
4.

Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use.

Lock D, Mockel-Tenbrinck N, Drechsel K, Barth C, Mauer D, Schaser T, Kolbe C, Al Rawashdeh W, Brauner J, Hardt O, Pflug N, Holtick U, Borchmann P, Assenmacher M, Kaiser A.

Hum Gene Ther. 2017 Oct;28(10):914-925. doi: 10.1089/hum.2017.111.

PMID:
28847167
5.

Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review.

Al-Sawaf O, Cramer P, Goede V, Hallek M, Pflug N.

Ther Adv Hematol. 2017 Jun;8(6):197-205. doi: 10.1177/2040620717699365. Epub 2017 Mar 30. Review.

6.

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy.

Al-Sawaf O, Fischer K, Engelke A, Pflug N, Hallek M, Goede V.

Drug Des Devel Ther. 2017 Jan 25;11:295-304. doi: 10.2147/DDDT.S104869. eCollection 2017. Review.

7.

Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML.

Holtick U, Herling M, Pflug N, Chakupurakal G, Leitzke S, Wolf D, Hallek M, Scheid C, Chemnitz JM.

Ann Hematol. 2017 Mar;96(3):479-487. doi: 10.1007/s00277-016-2887-4. Epub 2016 Dec 1.

PMID:
27909887
8.

Correction to Environmental Photochemistry of Altrenogest: Photoisomerization to a Bioactive Product with Increased Environmental Persistence via Reversible Photohydration.

Wammer KH, Anderson KC, Erickson PR, Kliegman S, Moffatt ME, Berg SM, Heitzman JA, Pflug NC, McNeill K, Martinovic-Weigelt D, Abagyan R, Cwiertny DM, Kolodziej EP.

Environ Sci Technol. 2016 Sep 20;50(18):10292. doi: 10.1021/acs.est.6b04213. Epub 2016 Sep 8. No abstract available.

PMID:
27604407
9.

Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota.

Pflug N, Kluth S, Vehreschild JJ, Bahlo J, Tacke D, Biehl L, Eichhorst B, Fischer K, Cramer P, Fink AM, von Bergwelt-Baildon M, Stilgenbauer S, Hallek M, Cornely OA, Vehreschild MJ.

Oncoimmunology. 2016 Apr 22;5(6):e1150399. doi: 10.1080/2162402X.2016.1150399. eCollection 2016 Jun.

10.

Environmental Photochemistry of Altrenogest: Photoisomerization to a Bioactive Product with Increased Environmental Persistence via Reversible Photohydration.

Wammer KH, Anderson KC, Erickson PR, Kliegman S, Moffatt ME, Berg SM, Heitzman JA, Pflug NC, McNeill K, Martinovic-Weigelt D, Abagyan R, Cwiertny DM, Kolodziej EP.

Environ Sci Technol. 2016 Jul 19;50(14):7480-8. doi: 10.1021/acs.est.6b02608. Epub 2016 Jul 11. Erratum in: Environ Sci Technol. 2016 Sep 20;50(18):10292.

11.

Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL.

Maurer C, Langerbeins P, Bahlo J, Cramer P, Fink AM, Pflug N, Engelke A, von Tresckow J, Kovacs G, Stilgenbauer S, Wendtner CM, Müller L, Ritgen M, Seiler T, Fischer K, Hallek M, Eichhorst B.

Leukemia. 2016 Oct;30(10):2019-2025. doi: 10.1038/leu.2016.113. Epub 2016 May 2.

PMID:
27133817
12.

Tuning Side Arm Electronics in Unsymmetrical Cyclotriazadisulfonamide (CADA) Endoplasmic Reticulum (ER) Translocation Inhibitors to Improve their Human Cluster of Differentiation 4 (CD4) Receptor Down-Modulating Potencies.

Chawla R, Van Puyenbroeck V, Pflug NC, Sama A, Ali R, Schols D, Vermeire K, Bell TW.

J Med Chem. 2016 Mar 24;59(6):2633-47. doi: 10.1021/acs.jmedchem.5b01832. Epub 2016 Mar 14.

PMID:
26974263
13.

Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.

Maurer C, Pflug N, Bahlo J, Kluth S, Rhein C, Cramer P, Gross-Ophoff C, Langerbeins P, Fink AM, Eichhorst B, Kreuzer KA, Fischer N, Tausch E, Stilgenbauer S, Böttcher S, Döhner H, Kneba M, Dreyling M, Binder M, Hallek M, Wendtner CM, Bergmann M, Fischer K; German CLL Study Group.

Eur J Haematol. 2016 Sep;97(3):253-60. doi: 10.1111/ejh.12714. Epub 2016 Feb 9.

PMID:
26643449
14.

Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).

Cramer P, Isfort S, Bahlo J, Stilgenbauer S, Döhner H, Bergmann M, Stauch M, Kneba M, Lange E, Langerbeins P, Pflug N, Kovacs G, Goede V, Fink AM, Elter T, Fischer K, Wendtner CM, Hallek M, Eichhorst B.

Haematologica. 2015 Nov;100(11):1451-9. doi: 10.3324/haematol.2015.124693. Epub 2015 Aug 27.

15.

The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression.

Langerbeins P, Bahlo J, Rhein C, Cramer P, Pflug N, Fischer K, Stilgenbauer S, Kreuzer KA, Wendtner CM, Eichhorst B, Hallek M.

Future Oncol. 2015;11(13):1895-903. doi: 10.2217/fon.15.95.

PMID:
26161926
16.

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.

Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, Bauer K, Malchau G, Rabe KG, Stilgenbauer S, Döhner H, Jäger U, Eckart MJ, Hopfinger G, Busch R, Fink AM, Wendtner CM, Fischer K, Kay NE, Hallek M.

Blood. 2014 Jul 3;124(1):49-62. doi: 10.1182/blood-2014-02-556399. Epub 2014 May 5.

17.

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab.

Fink AM, Böttcher S, Ritgen M, Fischer K, Pflug N, Eichhorst B, Wendtner CM, Winkler D, Bühler A, Zenz T, Staib P, Mayer J, Hensel M, Hopfinger G, Wenger M, Fingerle-Rowson G, Döhner H, Kneba M, Stilgenbauer S, Busch R, Hallek M.

Leukemia. 2013 Sep;27(9):1949-52. doi: 10.1038/leu.2013.190. Epub 2013 Jun 21. No abstract available.

18.

Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group.

Cramer P, Fink AM, Busch R, Eichhorst B, Wendtner CM, Pflug N, Langerbeins P, Bahlo J, Goede V, Schubert F, Döhner H, Stilgenbauer S, Dreger P, Kneba M, Böttcher S, Mayer J, Hallek M, Fischer K.

Leuk Lymphoma. 2013 Aug;54(8):1821-2. doi: 10.3109/10428194.2013.796050. Epub 2013 Jun 12.

PMID:
23631654
19.

Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia.

Hopfinger G, Busch R, Pflug N, Weit N, Westermann A, Fink AM, Cramer P, Reinart N, Winkler D, Fingerle-Rowson G, Stilgenbauer S, Döhner H, Kandler G, Eichhorst B, Hallek M, Herling M.

Cancer. 2013 Jun 15;119(12):2258-67. doi: 10.1002/cncr.27972. Epub 2013 Mar 19.

20.

State of the art treatment of chronic lymphocytic leukaemia.

Hallek M, Pflug N.

Blood Rev. 2011 Jan;25(1):1-9. doi: 10.1016/j.blre.2010.09.001. Epub 2010 Nov 20. Review.

PMID:
21095047
21.

Chronic lymphocytic leukemia.

Hallek M, Pflug N.

Ann Oncol. 2010 Oct;21 Suppl 7:vii154-64. doi: 10.1093/annonc/mdq373. Review.

PMID:
20943609

Supplemental Content

Support Center